CORONA sees hormone export payoff after a 2-3 year wait

Corona Remedies Limited said at its Q2 FY27 earnings call that its plan to prepare 10 to 12 hormone dossiers for regulated and semi-regulated markets should produce benefits in two to three years, as partner registrations alone can take one to two years. Management expects international revenue to remain below 10% of total revenue even then.

What is CORONA’s international expansion plan?

CORONA’s plan is to build an international hormone franchise through product dossiers and partner-led registrations, rather than seek an immediate broad-based export ramp-up. Management said it was at an advanced stage of preparing about 10 to 12 hormone dossiers for regulated and semi-regulated markets. It identified Europe, Brazil, Mexico, the Commonwealth of Independent States, Russia, Latin America and Asia as markets under consideration.

The route depends on registration after a dossier is supplied to a partner, rather than only exporting existing products. Management described the current international operation as a business-to-business model and said country-specific market and registration guidelines contributed to softer international growth in H1 FY27 and Q2 FY27. It nevertheless expects about 15% international revenue growth for the full year.

Q2 FY27 export business of Rs 12.6 crore was about half of the Rs 25.3 crore reported in H1 FY27. Management expects international business to reach Rs 60 crore to Rs 65 crore for the full year, based on its view of the order book, and then grow by about 15% in the following year. That near-term outlook is separate from the longer hormone-dossier programme.

Why did CORONA choose hormones for exports?

CORONA chose hormones because management links the category to its women’s healthcare presence in India, its investment in La Chandra and its Ahmedabad plant. Management said CORONA is one of the leading companies in women’s healthcare in India and has worked in and around hormones domestically. The overseas initiative therefore extends an existing therapeutic focus.

La Chandra is part of the supply-side rationale for the strategy. Management described La Chandra as a hormonal active pharmaceutical ingredient, or API, player and said there are few India-based API companies in hormones. CORONA said its investment brought a right of first offer and certain conditions, which management described as backward integration, while the Ahmedabad plant provides forward integration for finished products.

Management said the male-to-female ratio in hormone markets is broadly 50%-50% globally and in India. It expressed the view that economic development and environmental improvement could support hormone-market potential in India and worldwide. The immediate commercial step, however, is the preparation of 10 to 12 dossiers for overseas registrations.

When could CORONA’s hormone dossiers produce revenue?

CORONA expects the hormone programme to produce benefits in two to three years because registrations can take one to two years after dossiers are prepared and supplied to partners. Management said this regulatory route means dossier preparation should not be treated as immediate export revenue. The stated period covers the remaining preparation work and the subsequent registration process.

CORONA did not provide a date for its first approval, a country-by-country filing schedule or revenue expectations for individual dossiers. Management instead said it expected to receive the benefits in two to three years and retained India as the company’s core focus. Registrations are a stated gating mechanism because the strategy targets regulated and semi-regulated markets.

Management said international business would remain below 10% of CORONA’s total revenue even after the two-to-three-year period. Its domestic focus includes 33 Engine brands, which contributed 79% of business and were growing 22% internally. The export programme is therefore planned as an additional platform rather than a replacement for domestic growth.

How does the export plan fit CORONA’s domestic growth model?

CORONA’s domestic growth model remains based on growing at 1.5 times the Indian pharmaceutical market, or IPM, through volume, new introductions and price. Management said it expects IPM growth of 10% to 12% over the next three to four quarters, while characterising the expectation as its view rather than a confirmed market outcome. The company did not revise its 1.5-times-IPM revenue-growth guidance.

CORONA reported a 0.77% IPM market share, compared with about 8.5% for the number-one company. Management said its market share in core therapies was about 2.3%, while the market covered by those therapies was growing about 25% faster than IPM. These domestic opportunities underpin management’s expectation that international revenue will remain below 10% of the total.

CORONA added about 400 medical representatives in Q4 FY26, taking its field force to about 3,111 representatives, and said it has no current plan for another addition. In infertility, it deployed a 46-person task force that reached about Rs 7 lakh in its sales metric during its first six months, with a year-end expectation of Rs 8 lakh to Rs 9 lakh. Management said these investments support the India business while the export registration cycle progresses.

Conclusion

CORONA has set out a defined international strategy built around its hormone experience, La Chandra API relationship and Ahmedabad plant. The company plans to prepare 10 to 12 dossiers for partner-led registrations in markets including Europe, Brazil and Mexico, while Q2 FY27 exports of Rs 12.6 crore and H1 FY27 exports of Rs 25.3 crore show that the current international business remains small relative to its domestic Engine-brand base.

The next indicators are management’s expectation of Rs 60 crore to Rs 65 crore in international business for the full year and about 15% growth in the following year. Investors will also watch progress from dossier preparation to registrations, although management has not disclosed a filing calendar or first-approval date and expects the broader payoff only in two to three years.